Table 7.54Withdrawals

StudyTreatmentFollow-upOutcomesResult –best treatment
5 RCTs337,343, 345,339,341
Level 1+ and 334 Level 1++
Naproxen vs placebo12 weeksWithdrawals due to lack of efficacyNaproxen (all SS except Gibofsky = better)
1 RCT340
Level 1+
26 weeksNaproxen (better)
2 RCTs338, 343,345
Level 1+
12 weeksTotal number of withdrawalsNaproxen (better)
1 RCT337
Level 1+
Similar
1 RCT340
Level 1+
26 weeksNaproxen (better)
4 RCTs337,338, 343,345
Level 1+ and 334 Level 1++
12 weeksWithdrawals due to AEsNS
1 RCT341
Level 1+
Placebo (better)
1 RCT340
Level 1+
26 weeksNaproxen (better)
1 RCT343,345
Level 1+
12 weeksWithdrawals due to GI AEsPlacebo (better)
1 RCT342
Level 1+
Naproxen vs nabumetone12 weeksWithdrawals due to lack of efficacySimilar
Withdrawals due to treatment-related AEs and Total withdrawalsNS

From: 7, Pharmacological management

Cover of Rheumatoid Arthritis
Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults.
NICE Clinical Guidelines, No. 79.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2009, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.